Insomnia - 23/10/12
Doi : 10.1016/j.ncl.2012.08.012
Maryann C. Deak, MD ⁎ 
, John W. Winkelman, MD, PhD
, John W. Winkelman, MD, PhD Division of Sleep Medicine, Harvard Medical School, Sleep Health Centers, Brigham and Women's Hospital, 1505 Commonwealth Avenue, 5th Floor, Brighton, MA 02135, USA
Corresponding author.Résumé |
Insomnia is a common disorder, with individual and societal consequences. Advances have been made in the understanding of insomnia and its treatment options. However, cognitive behavioral therapy and Food and Drug Administration–approved pharmacologic therapies have limitations, the former primarily involving access and the latter involving potential side effects. Further research is needed to optimize management strategies.
Le texte complet de cet article est disponible en PDF.Keywords : Pharmacologic therapy, Cognitive behavioral therapy, For insomnia, Sleep disturbance
Plan
© 2012
Elsevier Inc. Tous droits réservés.
Vol 30 - N° 4
P. 1045-1066 - novembre 2012 Retour au numéro
Article précédent
- Hypersomnias of Central Origin
- Shelby F. Harris, Renee S. Monderer, Michael Thorpy
- Parasomnias and Their Mimics
- Raman K. Malhotra, Alon Y. Avidan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?